



September 25, 2026

To whom it may concern:

Company name: Kobayashi Pharmaceutical Co., Ltd.
Representative: Norikazu Toyoda, President & CEO
Securities code: 4967, Prime Market of Tokyo Stock Exchange
Tel: +81-6-6222-0142

Notice regarding Certain Media Reports

Certain media outlets reported yesterday on a potential take-private transaction involving the Company by Nippon Sangyo Suishin Kiko (NSSK) and CVC Capital Partners. Those reports were not based on any announcement made by the Company.

The Company has received a preliminary, non-binding joint proposal from entities affiliated with NSSK and CVC Capital Partners regarding a potential take-private transaction as a possible measure to enhance the Company's corporate value. However, no decision has been made by the Company at this time with respect to this matter.

In the event that any decision is made which requires disclosure, the Company will make an announcement promptly.

End